Encouraging Harm Reduction
To reduce morbidity and mortality associated with overdoses, FDA is:
- Expanding availability and access to overdose reversal products, including naloxone, by supporting accelerated review of products and exploring over-the-counter access
- Supporting development of novel overdose reversal products
- Supporting development and authorization of fentanyl test strips to test human specimens at the point of care
United States Government Partners
- Department of Health & Human Services (HHS)
- National Institutes of Health (NIH)
- Centers for Disease Control and Prevention (CDC)
- Centers for Medicare & Medicaid Services (CMS)
- Substance Abuse and Mental Health Services Administration (SAMHSA)
- Indian Health Service (IHS)
FDA Activities
- Naloxone and Nalmefene
- FDA Opioid Systems Modeling Effort
- Abuse-Deterrent Formulations
- Disposal of Unused Medicines: What You Should Know
- Safety Measures for Extended-release and Long-acting (ER/LA) Opioids
- Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)
- Safety Measures for Immediate Release (IR) Opioids
- Oxymorphone (marketed as Opana ER) Information
- SUPPORT Act Section 6012: Report on Abuse-Deterrent Opioid Formulations and Access Barriers Under Medicare (PDF - 698 KB)
- Safety Measures for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines